Marc E. Norman

Array ( [id] => 19855742 [patent_doc_number] => 12258566 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-25 [patent_title] => Oligonucleotides for PRNP modulation [patent_app_type] => utility [patent_app_number] => 17/187129 [patent_app_country] => US [patent_app_date] => 2021-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 45429 [patent_no_of_claims] => 50 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17187129 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17067582 [patent_doc_number] => 20210269797 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => METHODS AND COMPOSITIONS FOR TARGETING PD-L1 [patent_app_type] => utility [patent_app_number] => 17/249335 [patent_app_country] => US [patent_app_date] => 2021-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15448 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17249335 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16877989 [patent_doc_number] => 11028122 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2021-06-08 [patent_title] => Antisense nucleic acids [patent_app_type] => utility [patent_app_number] => 17/175276 [patent_app_country] => US [patent_app_date] => 2021-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 16785 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17175276 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17082393 [patent_doc_number] => 20210277399 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-09 [patent_title] => Methods of Imaging and Tracking Nucleic Acids in Cells [patent_app_type] => utility [patent_app_number] => 17/172480 [patent_app_country] => US [patent_app_date] => 2021-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8864 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 7 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17172480 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17312959 [patent_doc_number] => 20210402007 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => POLYNUCLEOTIDE AGENTS TARGETING HYDROXYACID OXIDASE (GLYCOLATE OXIDASE, HAO1) AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/166063 [patent_app_country] => US [patent_app_date] => 2021-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49401 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17166063 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18504855 [patent_doc_number] => 11702660 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-18 [patent_title] => Modulation of gene expression and screening for deregulated protein expression [patent_app_type] => utility [patent_app_number] => 17/159881 [patent_app_country] => US [patent_app_date] => 2021-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 69 [patent_no_of_words] => 37902 [patent_no_of_claims] => 47 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17159881 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20115023 [patent_doc_number] => 12364707 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-22 [patent_title] => Manipulation of eIF3 to modulate repeat associated non-ATG (RAN) translation [patent_app_type] => utility [patent_app_number] => 17/159288 [patent_app_country] => US [patent_app_date] => 2021-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 38 [patent_no_of_words] => 6781 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17159288 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17119830 [patent_doc_number] => 11130953 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-09-28 [patent_title] => Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/158375 [patent_app_country] => US [patent_app_date] => 2021-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 12 [patent_no_of_words] => 54066 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17158375 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17198728 [patent_doc_number] => 20210338822 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => THERAPEUTIC EXOSOMES AND METHOD OF PRODUCING THEM [patent_app_type] => utility [patent_app_number] => 17/156512 [patent_app_country] => US [patent_app_date] => 2021-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9035 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17156512 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19242179 [patent_doc_number] => 12012601 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-18 [patent_title] => Combination therapy with liposomal antisense oligonucleotides [patent_app_type] => utility [patent_app_number] => 17/150151 [patent_app_country] => US [patent_app_date] => 2021-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 17 [patent_no_of_words] => 30294 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17150151 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19027481 [patent_doc_number] => 11926828 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-12 [patent_title] => Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1 [patent_app_type] => utility [patent_app_number] => 17/150614 [patent_app_country] => US [patent_app_date] => 2021-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 14 [patent_no_of_words] => 42507 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 159 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17150614 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18230356 [patent_doc_number] => 20230069350 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-02 [patent_title] => METHODS AND COMPOSITIONS RELATING TO PROLONGED INFLAMMATORY INHIBITION AND/OR PROLONGED TREATMENT OF SPINAL PAIN BY CHIMERA DECOY [patent_app_type] => utility [patent_app_number] => 17/793377 [patent_app_country] => US [patent_app_date] => 2021-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18023 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17793377 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19505164 [patent_doc_number] => 12116576 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-15 [patent_title] => Oligonucleotides for modulating SCN9A expression [patent_app_type] => utility [patent_app_number] => 17/130451 [patent_app_country] => US [patent_app_date] => 2020-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37245 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 128 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17130451 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16900743 [patent_doc_number] => 20210179659 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-17 [patent_title] => ANTISENSE NUCLEIC ACIDS [patent_app_type] => utility [patent_app_number] => 17/126366 [patent_app_country] => US [patent_app_date] => 2020-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16573 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 225 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17126366 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16916293 [patent_doc_number] => 20210189385 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-24 [patent_title] => CLOSED LOOP CONTINUOUS APTAMER DEVELOPMENT SYSTEM [patent_app_type] => utility [patent_app_number] => 17/126842 [patent_app_country] => US [patent_app_date] => 2020-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10313 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 130 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17126842 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18071587 [patent_doc_number] => 11530411 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-20 [patent_title] => Methods for reducing LRRK2 expression [patent_app_type] => utility [patent_app_number] => 17/125738 [patent_app_country] => US [patent_app_date] => 2020-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14899 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17125738 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17657421 [patent_doc_number] => 20220177886 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-09 [patent_title] => APTAMERS AGAINST CLOSTRIDIUM DIFFICILE, COMPOSITIONS COMPRISING APTAMERS AGAINST CLOSTRIDIUM DIFFICILE AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 17/111067 [patent_app_country] => US [patent_app_date] => 2020-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52220 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17111067 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17124337 [patent_doc_number] => 20210299105 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-30 [patent_title] => SELECTIVE INHIBITION OF T FOLLICULAR HELPER CELLS FOR TREATMENT OF AUTOIMMUNE DISORDERS [patent_app_type] => utility [patent_app_number] => 17/110023 [patent_app_country] => US [patent_app_date] => 2020-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23223 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17110023 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19166004 [patent_doc_number] => 11981894 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-05-14 [patent_title] => Antisense nucleic acids [patent_app_type] => utility [patent_app_number] => 16/950449 [patent_app_country] => US [patent_app_date] => 2020-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 25 [patent_no_of_words] => 14724 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16950449 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18036562 [patent_doc_number] => 20220380777 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-01 [patent_title] => EXON SKIPPING OF FC-EPSILON-RI-BETA AND MS4A6A IN COMBINATION FOR THE TREATMENT OF ALLERGIC DISEASES [patent_app_type] => utility [patent_app_number] => 17/775136 [patent_app_country] => US [patent_app_date] => 2020-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23781 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -79 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17775136 [rel_patent_id] =>[rel_patent_doc_number] =>)